Relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection Addition of relacorilant did ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, ...
Please provide your email address to receive an email when new articles are posted on . The FDA issued a complete response letter for relacorilant to treat hypertension tied to hypercortisolism. The ...
Relacorilant plus Abraxane showed benefit without biomarker testing, potentially expanding treatment access for patients with platinum-resistant ovarian cancer. Treatment with relacorilant plus ...
Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ...
Results from ROSELLA showed a 35% reduction in the risk of death in patients treated with relacorilant plus nab-paclitaxel compared with nab-paclitaxel alone. Treatment with relacorilant, an ...
SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood pressure, fasting glucose, and weight for patients with adrenal ...
Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results